Serum levels of tumor-associated glycoprotein (TAG-72) in patients with carcinoma have been investigated by an immunoradiometric assay (IRMA), CA72-4, utilizing anti-TAG-72 monoclonal antibodies (MoAbs) CC49 and B72.3. The cut-off value for CA72-4 assay was determined as 4.0 units/ml according to the mean+2SD (3.9 units/ml), and only 3% of healthy individuals (n=514) demonstrated elevated levels of TAG-72. The average concentration of serum TAG-72 in cancer patients (n=265) was 37.9 units/ml, much higher than that (2.6 units/ml) in patients without malignancy (n=212). Elevated TAG-72 was found in 48% of patients with gastric carcinoma, 52% with colorectal carcinoma, 46% with pancreatic carcinoma, 37% with breast carcinoma and 60% with ovarian carcinoma. Serum TAG-72 in patients with primary carcinoma was serially measured to determine plasma clearance, and the mean period of decrease to the cut-off value was 23.2 days after removal of the tumors. These results indicate that CA72-4 IRMA may be useful to defect serum TAG-72 antigen in patients with gastrointestinal, breast, ovarian and other epithelial malignancies.
|Number of pages||10|
|Journal||Journal of Tumor Marker Oncology|
|Publication status||Published - 1990|
ASJC Scopus subject areas
- Cancer Research